PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2

INTRODUCTION: Treatment of bortezomib (BTZ) improves the clinical outcomes of patients with multiple myeloma (MM). However, primary resistance and acquired resistance to BTZ frequently develop in patients with MM. PH domain leucine-rich repeat protein phosphatase (PHLPP) plays an important role in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao, Li, Chengyuan, Fu, Yunfeng, Liu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969690/
https://www.ncbi.nlm.nih.gov/pubmed/32021285
http://dx.doi.org/10.2147/OTT.S237343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969690/
https://www.ncbi.nlm.nih.gov/pubmed/32021285
http://dx.doi.org/10.2147/OTT.S237343

Ejemplares similares